RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
   Rofecoxib
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Anti-Inflammatory Channel

subscribe to Anti-Inflammatory newsletter
Latest Research : Pharmacology : Anti-Inflammatory

   EMAIL   |   PRINT
Research Shows that FDA’s New Recommendations will Benefit COX-2 Inhibitors Though Physicians and Patients Remain Hesitant

Mar 24, 2005 - 9:48:00 AM
Physicians and Patients Remain Uncertain about COX-2s
Both physicians and patients remain cautious about COX-2s. Overall, physicians are still undecided about whether the benefits of COX-2s outweigh their drawbacks.

 
[RxPG] New FDA Advisory Committee Recommendations around COX-2s are likely to lead to prescribing gains for Bextra and Celebrex, though both physicians and patients will continue to shy away from Vioxx, even if it returns to market.New NOP World Health research shows that physicians, particularly general and family practitioners, anticipate increasing their Bextra prescribing, while internists, rheumatologists and orthopedic surgeons expect to boost their Celebrex prescribing.Patients taking Celebrex or Bextra are loyal to those products and plan to continue taking them.

Vioxx, however, will experience ongoing difficulties, even if Merck decides to reintroduce it. If Vioxx returns to market, most patients indicated they would be unwilling to take it—and most physicians would use it primarily as a second-line treatment, after Celebrex and Bextra.

Rheumatologists are most likely to return to Vioxx, if it once again becomes available.In contrast, a third of orthopedic surgeons say they will not prescribe Vioxx, if it is reintroduced.

“If Vioxx comes back to market, lingering concerns about cardiovascular risks may limit its potential,” according to Keith Loehlein, Senior Vice President of NOP World Health’s Market Assessment Practice.“To re-establish the product, Merck will have to ease fears about cardiovascular side effects.A good promotional starting point would be marketing first to rheumatologists—who are most receptive to a Vioxx return—before targeting primary care physicians or other specialists."

“Educational programs on the outcomes of the FDA’s recommendations also could be useful communications tools for influencing both physicians and patients.The FDA’s stance that all DTC advertising for COX-2s should be banned will make it difficult, however, for manufacturers to reach patients directly.”

Physicians and Patients Remain Uncertain about COX-2s
Both physicians and patients remain cautious about COX-2s. Overall, physicians are still undecided about whether the benefits of COX-2s outweigh their drawbacks.

Patients echo the concerns of many physicians. Former Vioxx users are particularly skeptical and unlikely to be swayed by the FDA’s recommendations.Patients taking pain medications other than COX-2s also are highly suspicious of the category—and findings indicate that manufacturers will have to make significant efforts to change those negative perceptions.

Unsure about COX-2s, many patients are turning to their doctors for answers. Rheumatologists report that 2 out of 3 patients have inquired about the Vioxx return.Questions tend to focus on comparisons between the COX-2s and the cardiovascular risks surrounding Vioxx.

New FDA Advisory Committee Recommendations Spur Research
NOP World Health conducted its research after an FDA Advisory Committee issued new recommendations on February 18, 2005, about the marketing of COX-2 Inhibitors.

The FDA decided that Celebrex and Bextra could remain on the market—and that Vioxx could potentially return.All three products, however, must now carry a black box warning about the increased risk of cardiovascular events. Overall, the committee agreed that, while the cardiovascular risk is a class effect, variations in that risk—based on specific drugs and dosages—necessitate a case-by-case consideration of COX-2 agents.

NOP World Health’s research provides an early read on physician and patient reactions to the panel’s recommendations.Both physician and patient studies were conducted via Internet.

The physician study was performed between February 24 and 28, 2005 among 200 doctors, including 50 internists…50 general and family practitioners…50 rheumatologists…and 50 orthopedic surgeons. The patient research was conducted between March 1 and 3, 2005 among 300 patients who have taken a prescription pain medication in the last nine months—116 of whom had taken a COX-2.



Publication: FDA Advisory Committee
On the web: NOP World Health  

Advertise in this space for $10 per month. Contact us today.


Related Anti-Inflammatory News
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
Ibuprofen - worsening cognitive function
COX 2 inhibitors associated with increased risk of vascular events
Therapeutic prospects beyond COX -2 inhibitors
Ceramide Kinase (CERK) may be a target for new anti-inflammatory drugs
No evidence for greater stomach protection by Cox-2 Inhibitors
European Medicines Agency update on non-selective NSAIDs
NSAIDS and Cox 2 inhibitors increase risk of MI - Study
Eszopiclone Cost Effective in Long-Term Treatment of Insomnia
FDA asks Pfizer to withdraw Bextra and add boxed warning to Celebrex

Subscribe to Anti-Inflammatory Newsletter

Enter your email address:


 Additional information about the news article
A leading supplier of primary research to the global healthcare community, NOP World Health is the health-focused arm of NOP World—a top-ten market research power worldwide. Bringing together some of the most renowned US and European research firms in a unified global network, NOP World is a wholly-owned subsidiary of UK-based United Business Media plc.

NOP World Health provides a unique mix of custom and multi-client solutions that reveal the “whys” driving market results. Services support the full marketing continuum, including market assessment…brand tracking…sales force effectiveness…healthcare consumer…and product launch applications.
To learn more about NOP World Health, visit their Web site, or contact Ilene Siegalovsky, NOP World’s Senior Vice President of Marketing, at 800-456-4405, ext. 3515 or [email protected]
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)